Impact of DNA damage repair defects and aggressive variant features on response to carboplatin‐based chemotherapy in metastatic castration‐resistant prostate cancer

Platinum‐based chemotherapy is not standard of care for unselected or genetically selected metastatic castration‐resistant prostate cancer (mCRPC) patients. A retrospective assessment of 71 patients was performed on platinum use in the Netherlands. Genetically unselected patients yielded low respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Slootbeek, Peter H. J., Duizer, Marleen L., van der Doelen, Maarten J., Kloots, Iris S. H., Kuppen, Malou C. P., Westgeest, Hans M., Uyl‐de Groot, Carin A., Pamidimarri Naga, Samhita, Ligtenberg, Marjolijn J. L., van Oort, Inge M., Gerritsen, Winald R., Schalken, Jack A., Kroeze, Leonie I., Bloemendal, Haiko J., Mehra, Niven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Cancer Genetics and Epigenetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756382/
https://www.ncbi.nlm.nih.gov/pubmed/32965028
http://dx.doi.org/10.1002/ijc.33306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756382/
https://www.ncbi.nlm.nih.gov/pubmed/32965028
http://dx.doi.org/10.1002/ijc.33306

Ejemplares similares